Additional file 4: of Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study
Table S2. Antihypertensive medications (other than ACEIs and ARBs) for patients with HBV and HCV within 6Â months after antihypertensive treatment, as grouped according to ACEI or ARB use within 6Â months after the index date. (DOCX 20Â kb)
Ho, C. (Contributor), Lee, C. (Contributor), Lee, M. (Contributor), Zhang, J. (Contributor), Wang, J. (Contributor), Hu, R. (Contributor), Lee, P. (Contributor) (Apr 10 2018). Additional file 4: of Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. Unknown Publisher. 10.6084/m9.figshare.6119192.v1